ArticleCancer science2010

Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.

Chuandong Ma et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.